Boxer Capital, LLC
- SEC CIK
- 0001465837
- Latest filing
- Feb 14, 2025
The latest 13F from Boxer Capital, LLC covers Q4 2024 (filed Feb 14, 2025) and reports no long positions. Livermore has 16 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q4 2024
Share counts compared with Q3 2024: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 68
- Est. −$2.04B
Top 5 holdings
Share of this quarter's portfolio value
This filing reports no long positions.
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q4 2024, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $0
- −$2.04B (−100.0%) vs. prior quarter
- Positions
- 0
- −68 vs. prior quarter
- Top 10 concentration
- –
- Top 10 as share of value
- Turnover
- 0.0%
- Q4 2024, one quarter
- Average holding period
- –
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
16 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $2.95B (Q1 2021)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q4 2024 | Feb 14, 2025 | 0 | $0 | – | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 68 | $2.04B | RVMDTYRANUVL | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 61 | $1.90B | RVMDSWTXCYTK | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 59 | $2.02B | SWTXCYTKRVMD | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 52 | $2.01B | MRTXCYTKSWTX | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 73 | $1.88B | MRTXRVMDONC | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 79 | $2.16B | RETAAPLSRVMD | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 75 | $2.04B | RXDXRETAONC | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 71 | $1.86B | RXDXONCCYTK | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 73 | $1.78B | MRTXCYTKRXDX | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 76 | $1.58B | MRTXCYTKONC | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 74 | $1.95B | MRTXSWTXITOS | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 70 | $2.51B | MRTXState Street SPDR S&P Biotech ETFITOS | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 87 | $2.86B | MRTXONCSWTX | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 95 | $2.83B | MRTXONCSWTX | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 85 | $2.95B | MRTXONCRVMD | – | SEC |
13D and 13G filings
Companies where Boxer Capital, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Boxer Capital, LLC does not currently report owning 5% or more of any company.
Latest filings
60 filings on file made by Boxer Capital, LLC or listing it as a reporting person; the latest 20 are shown.
| Company | Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|---|
| TILInstil Bio, Inc. | May 15, 20257:34 PM ET | Boxer Capital Management, LLCand 5 others | 13G/A | 1.20%80.1K shares | –Below 5% | May 9, 2025 | SEC |
| ITOSiTeos Therapeutics, Inc. | May 14, 2024 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| IPSCCentury Therapeutics, Inc. | Apr 22, 2024 | Boxer Capital, LLC | 13GOld format | – | New | – | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Feb 14, 2024 | Boxer Capital, LLC | 13G/AOld format | – | – | – | SEC |
| FATEFate Therapeutics Inc | Feb 12, 2024 | Boxer Capital, LLC | 13GOld format | – | New | – | SEC |
| TYRATyra Biosciences, Inc. | Feb 8, 2024 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| MRTXMirati Therapeutics, Inc. | Jan 25, 2024 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| NKTXNkarta, Inc. | Jan 18, 2024 | Boxer Capital, LLC | 13GOld format | – | New | – | SEC |
| Rain Oncology Inc. | Dec 18, 2023 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| MRTXMirati Therapeutics, Inc. | Oct 12, 2023 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| MRTXMirati Therapeutics, Inc. | Aug 16, 2023 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| Rain Oncology Inc. | May 25, 2023 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| MISTMilestone Pharmaceuticals Inc. | Feb 14, 2023 | Boxer Capital, LLC | 13G/AOld format | – | – | – | SEC |
| IDYAIDEAYA Biosciences, Inc. | Feb 14, 2023 | Boxer Capital, LLC | 13G/AOld format | – | – | – | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Feb 14, 2023 | Boxer Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Rain Oncology Inc. | Nov 8, 2022 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| SWTXSpringWorks Therapeutics, Inc. | Sep 19, 2022 | Boxer Capital, LLC | 13GOld format | – | New | – | SEC |
| TYRATyra Biosciences, Inc. | Jun 16, 2022 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| ITOSiTeos Therapeutics, Inc. | May 11, 2022 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |
| ITOSiTeos Therapeutics, Inc. | Mar 21, 2022 | Boxer Capital, LLC | 13D/AOld format | – | – | – | SEC |